Free access

Research Article

29 March 2019

Cost–effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China

Authors: Zhanwu Yu, Yu Liu, Ying Cui, Rui Ma, Huan Zhan, Wendong Chen, and Hongxu Liu [email protected]Author Info & Affiliations

Publication: J. Comp. Eff. Res.

Volume 8, Number 7

https://doi.org/10.2217/cer-2018-0127

PDF OtherFormats

Abstract

Aim: To assess the cost–effectiveness of standard utilization of zoledronic acid (ZA) relative to real-world utilization of ZA for bone metastasis (BM) in Chinese patients with advanced lung cancer. Materials & methods: A decision analytic model was constructed to simulate health benefits and medical costs associated with standard and real-world utilization of ZA for BM in Chinese patients with advanced lung cancer. Results: Compared with real-world utilization of ZA, standard utilization of ZA reduced cumulative risk of skeletal-related events (45.7 vs 63.6%), increased quality-adjusted life years (0.673 vs 0.626 QALY) and saved cumulated medical costs (¥343,163 vs ¥376,943). Conclusion: Standard utilization of ZA dominated real-world utilization of ZA for BM in Chinese patients with advanced lung cancer from cost–effectiveness perspective.

Formats available

You can view the full content in the following formats:

View PDF View Full Text

References

1.

Chen W, Zheng R, Peter D, Baade PD et al. Cancer Statistics in China, 2015. CA Cancer J. Clin. 66, 115–132 (2016).

2.

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243s–6249s (2006).

3.

Cetin K, Christiansen CF, Jacobsen JB et al. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 86(2), 247–254 (2014).

4.

Matza LS, Chung K, Van Brunt K et al. Health state utilities for skeletal-related events secondary to bone metastases. Eur. J. Health Econ. 15(1), 7–18 (2014).

5.

Decroisette C, Monnet I, Berard H et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J. Thorac. Oncol. 6(3), 576–582 (2011).

6.

Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl. 7), vii56–64 (2012).

7.

Joshi AD, Carter JA, Botteman MF, Kaura S. Cost–effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clin. Ther. 33(3), 291–304 (2011).

8.

Utilization of bisphosphonates for bone metastasis in Chinese lung cancer and breast cancer patients. IMS market research (2013).

9.

China guidelines for pharmacoeconomic evaluations. www.ispor.org/PEguidelines/source/China-Guidelines-for-PharmacoeconomicEvaluations_2011_Chinese.pdf.

10.

Scott D, Andrew L, Mel W. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 62(3), 374 (2008).

11.

Hillner BE, Weeks JC, Desch CE et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost–effectiveness analysis. J. Clin. Oncol. 18(1), 72 (2000).

12.

Yang Y, Ma Y, Jin S et al. A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China. Cancer 35(5), 40 (2016).

13.

Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat. Clin. Pract. Oncol. 6(3), 163–174 (2009).

14.

Santini D, Barni S, Intagliata S et al. Natural history of non-small-cell lung cancer with bone metastases. Sci. Rep. UK 22(5), 18670 (2015).

15.

Gaze MN, Kelly CG, Kerr GR et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother. Oncol. 45(2), 109–116 (1997).

16.

Delea T, Langer C, McKiernan J et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67(5-6), 390–396 (2004).

17.

Xiao S. The Impact of reimbursement on the financial burden of the lung cancer patients living in Wuhan city (Doctoral Dissertation). The Central China Technology University, Wuhan, China (2010).

18.

Qiu Q. Health economic evaluation of the new reimbursement policy on antiviral therapy for chronic hepatitis B in Beijing (Doctoral Dissertation). The Chinese Academy of Medical Sciences, Beijing, China (2015).

19.

Lo Faro AF, Giorgetti R, Busardò FP et al. Development and validation of a method using ultra performance liquid chromatography coupled to tandem mass spectrometry for determination of zoledronic acid concentration in human bone. J. Pharm. Biomed. Anal. 162, 286–290 (2019).

|